Berberine Improves Insulin Sensitivity by Inhibiting Fat Store and Adjusting Adipokines Profile in Human Preadipocytes and Metabolic Syndrome Patients

First Affiliated Hospital, Shanxi University of Medical, Taiyuan 030001, China.
Evidence-based Complementary and Alternative Medicine (Impact Factor: 1.88). 03/2012; 2012(6):363845. DOI: 10.1155/2012/363845
Source: PubMed


Berberine is known to inhibit the differentiation of 3T3-L1 cells in vitro, improve glycemic control, and attenuate dyslipidemia in clinical study. The aim of this study was to investigate the effects of berberine on preadipocytes isolated from human omental fat and in metabolic syndrome patients treated with berberine for 3 months. We have shown that treatment with 10 μM berberine resulted in a major inhibition of human preadipocyte differentiation and leptin and adiponectin secretion accompanied by downregulation of PPARγ2, C/EBPα, adiponectin, and leptin mRNA expression. After 3 months of treatment, metabolic syndrome patients showed decrease in their BMI (31.5 ± 3.6 versus 27.4 ± 2.4 kg/m(2)) and leptin levels (8.01 versus 5.12 μg/L), as well as leptin/adiponectin ratio and HOMA-IR. These results suggest that berberine improves insulin sensitivity by inhibiting fat store and adjusting adipokine profile in human preadipocytes and metabolic syndrome patients.

Download full-text


Available from: Ming Li,
32 Reads
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Chemical compounds derived from plants have been used since the origin of human beings to counteract a number of diseases. Among them, the natural isoquinoline alkaloid berberine has been employed in Ayurvedic and Chinese Medicine for hundreds of years with a wide range of pharmacological and biochemical effects. More recently, a growing body of reports supports the evidence that berberine has anticancer effects, being able to block the proliferation of and to kill cancer cells. This review addresses the properties and therapeutic use of berberine and focuses on the recent advances as promising anticancer drug lead.
    Biochemical pharmacology 07/2012; 84(10):1260-7. DOI:10.1016/j.bcp.2012.07.018 · 5.01 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Background Primary cardiovascular prevention may be achieved by lifestyle/nutrition improvements and specific drugs, although a relevant role is now emerging for specific functional foods and nutraceuticals. Objectives Aim of this study was to evaluate the usefulness of a nutraceutical multitarget approach in subjects with moderate cardiovascular risk and to compare it with pravastatin treatment. Subjects Thirty patients with moderate dyslipidemia and metabolic syndrome (NCEP ATPIII) were included in an 8-week randomized, double-blind cross-over study and took either placebo or a nutraceutical combination containing red yeast rice extract, berberine, policosanol, astaxanthin, coenzyme Q10 and folic acid (Armolipid Plus®). Subsequently, they were subjected to another 8-week treatment with 10 mg/day pravastatin. This dose was selected based upon its expected -20% efficacy in reducing LDL-cholesterol. Results Treatment with Armolipid Plus led to a significant reduction of total cholesterol (-12.8%) and LDL-cholesterol (-21.1%), similar to pravastatin (-16% and -22.6%, respectively), and an increase of HDL-cholesterol (+4.8%). Armolipid Plus improved the leptin/adiponectin ratio, whereas adiponectin levels were unchanged. Conclusions These results indicate that this nutraceutical approach shows a lipid-lowering activity comparable to pravastatin treatment. Hence, it may be a safe and useful option, especially in conditions of moderate cardiovascular risk, in which a pharmacological intervention may not be appropriate.
    Journal of Clinical Lipidology 01/2013; 8(1). DOI:10.1016/j.jacl.2013.11.003 · 3.90 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Berberine (BBR), an active ingredient from nature plants, has demonstrated multiple biological activities and pharmacological effects in a series of metabolic diseases including nonalcoholic fatty liver disease (NAFLD). The recent literature points out that BBR may be a potential drug for NAFLD in both experimental models and clinical trials. This review highlights important discoveries of BBR in this increasing disease and addresses the relevant targets of BBR on NAFLD which links to insulin pathway, adenosine monophosphate-activated protein kinase (AMPK) signaling, gut environment, hepatic lipid transportation, among others. Developing nuanced understanding of the mechanisms will help to optimize more targeted and effective clinical application of BBR for NAFLD.
    Evidence-based Complementary and Alternative Medicine 06/2013; 2013:308134. DOI:10.1155/2013/308134 · 1.88 Impact Factor
Show more